

glossary

Progression-free survival A term referring to the length of time, during and after treatment, a cancer does not grow

Pulmonary embolism Blood clot in one of the major arteries that carry blood depleted of oxygen to the lungs

R

Remission Referring to the absence of active cancer

S

Sanofi-Aventis The Pharmaceutical Company that produces Lovenox®

Scale-up Production of large, industrial, quantities of a drug

Secondary endpoint A clinical endpoint supportive of the primary endpoint, through additional clinical characterisation of the treatment effect

Statistical significance A result from a statistical test which indicates whether differences between experimental groups are real or due to chance

Super generic A "high-barrier-to-entry" generic product, differing from the original in formulation or method of delivery

Synthesis The formation of a man made chemical compound from simpler compounds by chemical reactions, usually over a number of steps

T

TGA Therapeutic Goods Administration. The Australian Government agency which assesses and monitors activities to ensure medicines in Australia are of an acceptable standard

Thrombosis A blood vessel blockage by a clot formed at the site of obstruction. This is distinguished from an "embolism", which travels through the bloodstream and lodges, obstructing a blood vessel

Time to treatment failure An aggregate end point comprised of time to disease progression, time to toxicity or death, or time to initiation of alternate therapy

Tumour An abnormal mass of tissue that results from excessive cell division. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant (cancerous)

Tumour response Evidence of tumour shrinkage by clinical or radiological data

V

VAST® Versatile Assembly on Stable Templates. Alchemia's carbohydrate based drug discovery platform technology. VAST® enables rapid synthesis of libraries of compounds that effectively scan three dimensional space

acronyms

ANDA

Abbreviated New Drug Application

AFSSAPS

Health Products Safety Agency (France)

CDER

Centre for Drug Evaluation & Research (FDA)

EMA

European Medicines Agency (Europe)

FDA

Food & Drug Administration (United States)

GMP

Good Manufacturing Practice

GPCR

g-Protein Coupled Receptor

GSK

GlaxoSmithKline

HTS

High Throughput Screening

IND

Investigational New Drug

LMWH

Low Molecular Weight Heparin

MPA

Medical Products' Agency (Sweden)

NCE

New Chemical Entity

NDA

New Drug Application

PFS

Progression Free Survival

TGA

Therapeutic Goods Administration (Australia)

VTE

Venous Thromboembolism